Holen Sie sich die Stockscreener-App
27.22
0.91%
-0.25
Vorhandelsmarkt:
27.25
0.03
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
PFIZER INC : Gets a Neutral rating from JP Morgan - marketscreener.com
Hemophilia B Pipeline 2026 Report Highlights Next-Gen Gene Therapies, FDA Advances, and Clinical Momentum Across Novo Nordisk, Pfizer, Sanofi & Emerging Biotechs | DelveInsight - Barchart.com
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders - The National Law Review
Pfizer (PFE) Analyst Rating Update: Target Price Lowered to $26 - GuruFocus
Pfizer Invites Shareholders to Virtual 2026 Annual Meeting - National Today
Pfizer shareholders can vote online at April 23 annual meeting - Stock Titan
BCAN Names Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting Sponsors of the 2026 Walks to End Bladder Cancer - The Manila Times
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
Is Pfizer (PFE) Offering Value After Its 31% One Year Share Price Jump - Yahoo Finance
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause - simplywall.st
Pfizer Inc Storebrand Conference: Invest in the Future Call Transcript - GuruFocus
Pfizer Options Spot-On: On April 8th, 90,399 Contracts Were Traded, With 2.45 Million Open Interest - Moomoo
Pfizer Inc. stock rises Wednesday, still underperforms market - MarketWatch
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results - Yahoo Finance
Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barchart
RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE) - The Globe and Mail
Why Pfizer Stock Tumbled on Tuesday - AOL.com
Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift - Yahoo Finance
Comirnaty: Pfizer-BioNTech COVID-19 Vaccine Explained - AD HOC NEWS
Belgian Court Ruling Extends Pfizer Covid Cash Flow And Legal Questions - simplywall.st
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Major biotech company shutting down South San Francisco office - KRON4
Biotech giant abandoning South San Francisco research site - SFGATE
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Pfizer Options Spot-On: On April 7th, 158.61K Contracts Were Traded, With 2.38 Million Open Interest - Moomoo
PFIZER INC (PFE.SW) Q1 FY2025 earnings call transcript - Yahoo Finance
Pfizer stock slides 2.52% as company highlights CDK research progress in metastatic breast cancer - Traders Union
Pfizer (PFE) Faces Bearish Sentiment Among Options Traders - GuruFocus
Pfizer Inc. (NYSE:PFE) Market Action Tied To S&P 500 Index Movement - Kalkine Media
Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment - TipRanks
Pfizer Targets Advanced Kidney Cancer With New PF-08634404 Trial: What Investors Should Know - TipRanks
What is behind Pfizer stock's recent drop in value today - Traders Union
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas - Yahoo Finance UK
Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today - The Globe and Mail
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart
RBC Capital reiterates Pfizer stock Underperform rating on product headwinds - Investing.com
RBC Capital Maintains Pfizer(PFE.US) With Sell Rating, Maintains Target Price $25 - Moomoo
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - GlobeNewswire Inc.
Pfizer to close South San Francisco research site by end of April - Yahoo Finance
Pfizer (NYSE:PFE) Stock Price Down 1.7%Here's What Happened - MarketBeat
Pfizer Inc. stock underperforms Monday when compared to competitors - MarketWatch
Pfizer Failed To Warn Of Depo-Provera Cancer Risk, Suit Says - Law360
Pfizer : Science Will Win season finale explores AI in cancer care with Pfizer Chief Oncology Officer Jeff Legos - marketscreener.com
High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout - Yahoo Finance
How AI Is Already Reshaping Cancer Care - Pfizer
Pfizer Inc. $PFE Shares Sold by Quilter Plc - MarketBeat
Pfizer Inc. $PFE Shares Sold by Stratos Wealth Partners LTD. - MarketBeat
Capricorn Fund Managers Ltd Invests $4.12 Million in Pfizer Inc. $PFE - MarketBeat
Comirnaty Vaccine: Pfizer-BioNTech COVID-19 Shot - AD HOC NEWS
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements - Yahoo Finance
PFE Stock Quote Price and Forecast - CNN
Raab & Moskowitz Asset Management LLC Sells 39,910 Shares of Pfizer Inc. $PFE - MarketBeat
SteelPeak Wealth LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer - Insider Monkey
Pfizer Inc. (PFE) latest press releases and corporate news - Yahoo Finance Singapore
How Pfizer’s Lyme Vaccine Trial Results Could Shape Pipeline Renewal for Pfizer (PFE) Investors - simplywall.st
Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change - Yahoo Finance
Pfizer Loses Bid to Dismiss Disability Bias Lawsuit - National Today
Pfizer Fails to Escape Warehouse Worker’s Disability Bias Suit - Bloomberg Law News
Ever Wonder How Medicines Get Their Names? - Pfizer
38,600 Shares in Pfizer Inc. $PFE Acquired by Genesis Financial Group LLC - MarketBeat
Pfizer Inc. $PFE Stock Position Reduced by First Pacific Financial - MarketBeat
0.45%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):